Skip to main content

Table 5 The association between hypertensive retinopathy and albuminuria by subgroupa

From: Positive correlation between hypertensive retinopathy and albuminuria in hypertensive adults

Subgroup

N

Albuminuria,

N (%)

 

Hypertensive retinopathy groups

p for interaction

Normal

Grade 1

Grade 2

Grade 3

 

OR (95% CI)

OR (95% CI)

OR (95% CI)

Sex

      

0.780

 Male

1070

94 (8.8)

ref

1.91(0.89,4.08)

2.34(0.96,5.71)

3.33(0.78,14.24)

 

 Female

1893

235 (12.4)

ref

1.49(0.96,2.32)

2.05(1.2,3.5)

1.78(0.71,4.49)

 

Age, years

      

0.147

  < 65

1769

163 (9.2)

ref

1.53(0.9,2.6)

2.33(1.27,4.29)

0.89(0.23,3.45)

 

  ≥ 65

1178

164 (13.9)

ref

1.69(0.98,2.91)

1.59(0.78,3.24)

4.1(1.52,11.06)

 

BMI, kg/m2

      

0.391

  < 24

1042

105 (10.1)

ref

1.1(0.58,2.07)

2.26(1.07,4.8)

1.29(0.29,5.63)

 

  ≥ 24, < 28

1178

134 (11.4)

ref

1.77(0.95,3.3)

2.17(1.03,4.6)

2.75(0.79,9.59)

 

  ≥ 28

728

90 (12.4)

ref

2.13(0.99,4.57)

1.49(0.58,3.85)

3.36(0.85,13.27)

 

Treatment group

      

0.184

 Enalapril

1255

123 (9.8)

ref

1.06(0.64,1.76)

1.45(0.77,2.7)

2.48(0.85,7.24)

 

 Enalapril + folic acid

1222

121 (9.9)

ref

2.48(1.27,4.82)

3.07(1.42,6.68)

2.8(0.85,9.23)

 

SBP, mmHg

      

0.785

  < 140

1686

137 (8.1)

ref

1.56(0.9,2.69)

2.37(1.24,4.55)

1.66(0.45,6.06)

 

  ≥ 140

1246

189 (15.2)

ref

1.63(0.96,2.77)

1.81(0.95,3.45)

2.54(0.94,6.83)

 

TG, mmol/L

      

0.014

  < 1.7

1722

158 (9.2)

ref

1.06(0.65,1.72)

1.28(0.68,2.39)

2.7(1.09,6.73)

 

  ≥ 1.7

1201

166 (13.8)

ref

2.58(1.36,4.9)

3.62(1.75,7.48)

1.08(0.22,5.38)

 

TCHO, mmol/L

      

0.237

  < 5.2

1259

126 (10.0)

ref

1.77(0.96,3.28)

2.59(1.24,5.41)

3.86(1.31,11.38)

 

  ≥ 5.2

1642

195 (11.9)

ref

1.43(0.88,2.32)

1.7(0.94,3.06)

1(0.31,3.22)

 

FBG, mmol/L

      

0.693

  < 7.0

2393

223 (9.3)

ref

1.47(0.95,2.27)

2.09(1.24,3.52)

1.98(0.71,5.54)

 

  ≥ 7.0

508

98 (19.3)

ref

1.94(0.88,4.28)

1.78(0.68,4.64)

2.97(0.89,9.95)

 

HCY, μmol/L

      

0.947

  < 10

686

75 (10.9)

ref

1.1(0.51,2.34)

1.63(0.65,4.13)

2.57(0.53,12.44)

 

  ≥ 10, < 15

1554

165 (10.6)

ref

1.61(0.97,2.68)

1.99(1.06,3.73)

1.76(0.62,5.01)

 

  ≥ 15

678

82 (12.1)

ref

2.24(0.89,5.66)

2.54(0.88,7.37)

4(0.63,25.19)

 

Hyperuricemia

      

0.528

 No

2303

251 (10.9)

ref

1.66(1.09,2.51)

1.85(1.1,3.1)

2.45(1.04,5.78)

 

 Yes

624

72 (11.5)

ref

1.65(0.64,4.24)

3.16(1.11,8.99)

1.41(0.23,8.66)

 

Smoking status

      

0.217

 Never

2094

245 (11.7)

ref

1.39(0.91,2.13)

1.77(1.05,2.99)

1.58(0.63,3.95)

 

 Former

284

29 (10.2)

ref

5.37(0.63,45.8)

4.81(0.45,51.81)

0(0,Inf)

 

 Current

569

55 (9.7)

ref

1.84(0.68,4.96)

3.17(1.04,9.67)

5.7(1,32.68)

 

Alcohol consumption

      

0.861

 Never

2089

242 (11.6)

ref

1.58(1.02,2.45)

2.01(1.18,3.41)

1.94(0.8,4.68)

 

 Former

168

27 (16.1)

ref

3.84(0.67,22.08)

4.06(0.45,36.69)

4.07(0.04,411.17)

 

 Current

575

52 (9)

ref

1.15(0.46,2.84)

2.12(0.74,6.09)

2.84(0.48,16.98)

 
  1. OR Odds ratio, CI Confidence intervals, BMI Body mass index, SBP Systolic blood pressure, TG Triglyceride, TCHO Total cholesterol, FBG Fasting blood glucose, HCY Homocysteine
  2. aAdjusted for age, sex, body mass index, systolic blood pressure, diastolic blood pressure, methylenetetrahydrofolate reductase C677T polymorphisms, total cholesterol, triglycerides, fasting blood glucose, estimated glomerular filtration rate, folate, homocysteine, smoking status, alcohol consumption, and the use of antihypertensive drugs